Medication bleeding disorders Flashcards
Tranexemic acid
Inhibits fibrinolysis by occupying lysin spot
VWD
DDAVP
Release from vWF and VIII from WP-bodies
VWD, exept type 2b
Side effects include headache, flushing, hypotension, fluid retention
Factor VIII and IX concentrates
Treatment of Hemophila A and B
Side effects of factor concentrates
Allergic reactions
Viral infections
Development of inhibitors
IgG antibody against VIII or IX
30% of severe hemophilia A and 5-10% hemophilia B
Within first 50 treatment days
FEIBA
VIII inhibitor bypassing activity
NovoSeven
Recombinant VIIa concentrate
Hemophilia A, B
Glanzmann thrombastania with decreased response to platelet infusions
LMWHK
Anticoagulant
Prevention of recurrent venous thrombosis
Aspirin, NSAID
Inhibition of platelet aggregation by inhibiting TXA2 formation
Asperin is irreversible, NSAID reversible
Clopidogrel
ADP receptor inhibitor > no platelet aggregation
Irreversible
Prasugel
ADP receptor inhibitor > no platelet aggregation
Irreversible
Ticagrelor
ADP receptor inhibitor > no platelet aggregation
Reversible
Emicuzimab
Takes over function of VIII
Hemophilia A
Insensitve to inhibitors
Andexanet alpha
Binds to Xa inhibitors, neutralizes their activity
Patients treated with Xa inhibitors, when there is life-threatening risk of bleeds
DOACs
Anticoagulants
Prevention of VTE after surgery and embolism in atrial fibrillation
Treatment of VT
